Alkermes Raises Revenue Forecast After Arbitration Award

By Ali Sullivan ( June 6, 2023, 9:03 PM EDT) -- Biopharmaceutical company Alkermes PLC on Tuesday boosted its financial forecast for 2023 by $425 million after the company said it wrapped arbitration proceedings with Johnson & Johnson subsidiary Janssen Pharmaceutica NV over two license agreements for small particle pharmaceutical compound technology that Janssen uses in antipsychotic, schizophrenia and HIV drugs. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Law360 is pleased to announce the Rising Stars of 2025, our list of more than 150 attorneys under 40 whose legal accomplishments belie their age.